Christoph Lengauer is a venture partner at Third Rock Ventures, the president of Celsius Therapeutics, and executive vice president at Blueprint Medicines. His conversation with Nature Biotechnology covers growing up in Austria, why he nearly gave up research for a career helping settle refuguees, and his role in the Henrietta Lacks story.
Rights and permissions
About this article
Cite this article
PODCAST: First rounders: Christoph Lengauer. Nat Biotechnol 36, 1030 (2018). https://doi.org/10.1038/nbt1118-1030b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1118-1030b